What is BioArctic AB (BRCTF)?

BioArctic AB (BRCTF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BRCTF?

The current price of BRCTF is $29.40. Prices are updated in real time on Stocks360.

What is BRCTF's price-to-earnings (PE) ratio?

BRCTF's trailing twelve-month PE ratio is 266.55, based on current price and earnings per share data available on Stocks360.

What is BRCTF's market capitalization?

BRCTF's market capitalization is $2,609,093,886.00, placing it in the mid-cap tier.

Does BRCTF pay a dividend?

Yes. BRCTF has a trailing twelve-month dividend yield of 0.01%. Dividend data is sourced from financial market providers and displayed on Stocks360.

BioArctic AB (BRCTF)

Stock analysis · OTC · Healthcare · Biotechnology

$29.40

Market Cap

$2.61B

PE (TTM)

266.55

EPS (TTM)

N/A

Dividend Yield

0.63%

Beta

-0.67

Day Range

$29.40 – $35.00

52-wk Range

$27.82 – $40.00

Avg Volume

N/A

Volume

250.00

BioArctic AB (BRCTF) is a publicly traded company in the Healthcare sector. Latest price: $29.40. Market cap $2.61B. Trailing PE 266.55. Dividend yield 0.63%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $32.16 2026-10-26 · $29.40 (-8.58%)

Earnings

Most Recent

Aug 26, 2026

EPS $-0.01 vs est. $-0.03

Beat by $0.02

Next Earnings

Nov 25, 2026

EPS estimate $0.03

Proprietary Signals

Signal snapshot temporarily unavailable.

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	266.55×
P/S (TTM)	28.08×
P/B	13.96×
P/FCF (TTM)	265.22×
EV / EBITDA	119.28×
EV / Sales	27.09×
Earnings Yield	0.37%
Free Cash Flow Yield	0.38%
Dividend Yield	0.63%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$27.16B
Revenue (TTM)	$1.00B
Net Income (TTM)	$105.55M
Free Cash Flow (TTM)	$247.84M
Net Debt	-$990.73M
Working Capital	$2.01B
Gross Margin	93.17%
Operating Margin	21.37%
Net Margin	10.53%
Return on Equity	5.18%
Return on Invested Capital	4.20%